Effects of nonstatin lipid drug therapy on high-density lipoprotein metabolism

American Journal of Cardiology

Volumn 91, Issue 7 SUPPL. 1, 2003, Pages 18-23

  Rader, Daniel J ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLESTIPOL; COLESTYRAMINE; ESTROGEN; FENOFIBRATE; FLUINDOSTATIN; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METFORMIN; MEVINOLIN; NICOTINIC ACID; OMEGA 3 FATTY ACID; PIOGLITAZONE; PRAVASTATIN; PROGESTERONE; ROSIGLITAZONE; SIMVASTATIN; THIAZOLIDINE DERIVATIVE; TROGLITAZONE;

CHOLESTEROL METABOLISM; CLINICAL TRIAL; CONFERENCE PAPER; CORONARY ARTERY DISEASE; DRUG EFFECT; DRUG POTENCY; DYSLIPIDEMIA; HUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK FACTOR;

EID: 0037417218     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(02)03384-2     Document Type: Conference Paper

References (42)

1. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 285:2001;2486-2497.
2. Belalcazar L.M., Ballantyne C.M. Defining specific goals of therapy in treating dyslipidemia in the patient with low high-density lipoprotein cholesterol. Prog Cardiovasc Dis. 41:1998;151-174.
3. Morgan J.M., Capuzzi D.M., Guyton J.R., Centor R.M., Goldberg R., Robbins D.C., DiPette D., Jenkins S., Marcovina S. Treatment effect of Niaspan, a controlled-release niacin, in patients with hypercholesterolemia a placebo-controlled trial . J Cardiovasc Pharmacol Ther. 3:1996;195-202.
4. Capuzzi D.M., Guyton J.R., Morgan J.M., Goldberg A.C., Kreisberg R.A., Brusco O.A., Brody J. Efficacy and safety of an extended-release niacin (Niaspan) a long-term study . Am J Cardiol. 82:1998;74U-81U.
5. Goldberg A., Alagona P., Capuzzi D.M., Guyton J., Morgan J.M., Rodgers J., Sachson R., Samuel P. Multiple-dose efficacy and safety of an extended-release form of niacin in the management of hyperlipidemia. Am J Cardiol. 85:2000;1100-1105.
6. Sprecher D.L. Raising high-density lipoprotein cholesterol with niacin and fibrates a comparative review . Am J Cardiol. 86:(suppl):2000;46L-50L.
7. Lavie C.J., Mailander L., Milani R.V. Marked benefit with sustained-release niacin therapy in patients with "isolated" very low levels of high-density lipoprotein cholesterol and coronary artery disease. Am J Cardiol. 62:1992;1083-1085.
8. King J.M., Crouse J.R., Terry J.G., Morgan T.M., Spray B.J., Miller N.E. Evaluation of effects of unmodified niacin on fasting and postprandial plasma lipids in normolipidemic men with hypoalphalipoproteinemia. Am J Med. 97:1994;323-331.
9. Hunninghake DB, McGovern ME, Simmons PD, Evans R, Batcheller AB, Cefali EA. Dose-ranging and dose-sparing effects of a once-daily formulation of lovastatin and extended-release niacin in patients with hyperlipidemia. In: Program and abstracts of the XIV International Symposium on Drugs Affecting Lipid Metabolism; September 9-12, 2001; New York, NY.
10. Insull W, Adams M, Evans R, Mcgovern M, Simmons P, Thompson E, Cefali E. Dose-response effects on high-density lipoprotein cholesterol and multiple other lipoproteins of a new, once-daily formulation of lovastatin and extended-release niacin in patients with primary hypercholesterolemia. In: Program and abstracts of the XIV International Symposium on Drugs Affecting Lipid Metabolism; September 9-12, 2001; New York, NY.
11. Jacobson T.A., Chin M., Fromell G.J., Jokubaitis L.A., Amorosa L.F. Fluvastatin with and without niacin for hypercholesterolemia. Am J Cardiol. 74:1994;149-154.
12. Brown B.G., Bardsley J., Poulin D., Hillger L.A., Dowdy A., Maher V.M., Zhao X.Q., Albers J.J., Knopp R.H. Moderate dose, three-drug therapy with niacin, lovastatin, and colestipol to reduce low-density lipoprotein cholesterol <100 mg/dL in patients with hyperlipidemia and coronary artery disease. Am J Cardiol. 80:1997;111-115.
13. Wolfe M.L., Vartanian S.F., Ross J.L., Bansavich L.L., Mohler E.R. III, Meagher E., Friedrich C.A., Rader D.J. Safety and effectiveness of Niaspan when added sequentially to a statin for treatment of dyslipidemia. Am J Cardiol. 87:2001;476-479.
14. Blum C.B., Levy R.L., Eisenberg S., Hall M. III, Goebel R.H., Berman M. High density lipoprotein metabolism in man. J Clin Invest. 60:1977;795-807.
15. Shepherd J., Packard C.J., Patsch J.R., Gotto A.M. Jr, Taunton O.D. Effects of nicotinic acid therapy on plasma high density lipoprotein subfraction distribution and composition and on apolipoprotein A metabolism. J Clin Invest. 63:1979;858-867.
16. Jin F.Y., Kamanna V.S., Kashyap M.L. Niacin decreases removal of high density lipoprotein apoprotein A-I but not cholesterol ester by Hep G2 cells implications for reverse cholesterol transport . Arterioscler Thromb Vasc Biol. 17:1997;2020-2028.
17. Rubins H.B., Robins S.J., Collins D., Fye C.L., Anderson J.W., Elam M.B., Faas F.H., Linares E., Schaefer E.J., Schectman G., Wilt T.J., Wittes J. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group . N Engl J Med. 341:1999;410-418.
18. Rader D.J., Haffner S.M. Role of fibrates in the management of hypertriglyceridemia. Am J Cardiol. 83(9B):1999;30F-35F.
19. Goldberg A.C., Schonfeld G., Feldman E.B., Ginsberg H.N., Hunninghake D.B., Insull W. Jr, Knopp R.H., Kwiterovich P.O., Mellies M.J., Pickering J. Fenofibrate for the treatment of type IV and V hyperlipoproteinemias a double-blind, placebo-controlled multicenter US study . Clin Ther. 11:1989;69-83.
20. Poulter N. The impact of micronized fenofibrate on lipid subfractions and on reaching HDL-target levels in 7098 patients with dyslipidaemia. Br J Cardiol. 6:1999;682-685.
21. Miller M., Bachorik P.S., McCrindle B.W., Kwiterovich P.O. Effect of gemfibrozil in men with primary isolated low high-density lipoprotein cholesterol a randomized, double-blind, placebo-controlled, crossover study . Am J Med. 94:1993;7-12.
22. Guyton J.R., Blazing M.A., Hagar J., Kashyap M.L., Knopp R.H., McKenney J.M., Nash D.T., Nash S.D. Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol Niaspan-Gemfibrozil Study Group . Arch Intern Med. 160:2000;1177-1184.
23. Vega G.L., Grundy S.M. Comparison of lovastatin and gemfibrozil in normolipidemic patients with hypoalphalipoproteinemia. JAMA. 262:1989;3148-3153.
24. Wierzbicki A.S., Lumb P.J., Cheung J., Crook M.A. Fenofibrate plus simvastatin therapy versus simvastatin plus cholestyramine therapy for familial hypercholesterolaemia. QJM. 90:1997;631-634.
25. Wiklund O., Angelin B., Bergman M., Berglund L., Bondjers G., Carlsson A., Linden T., Miettinen T., Odman B., Olofsson S.O. Pravastatin and gemfibrozil alone and in combination for the treatment of hypercholesterolemia. Am J Med. 94:1993;13-20.
26. Staels B., Dallongeville J., Auwerx J., Schoonjans K., Leitersdorf E., Fruchart J.-C. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation. 98:1998;2088-2093.
27. Chinetti G., Lestavel S., Bocher V., Remaley A.T., Neve B., Torra I.P., Teissier E., Minnich A., Jaye M., Duverger N., et al. PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat Med. 7:2001;53-58.
28. Rosenblatt S., Miskin B., Glazer N.B., Prince M.J., Robertson K.E. The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus. Coron Artery Dis. 12:2001;413-423.
29. Einhorn D., Rendell M., Rosenzweig J., Egan J.W., Mathisen A.L., Schneider R.L. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus a randomized, placebo-controlled study . Clin Ther. 22:2000;1395-1409.
30. Lebovitz H.E., Dole J.F., Patwardhan R., Rappaport E.B., Freed M.I. Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J Clin Endocrinol Metab. 86:2001;280-288.
31. Patel J., Anderson R.J., Rappaport E.B. Rosiglitazone monotherapy improves glycaemic control in patients with type 2 diabetes a twelve-week, randomized, placebo-controlled study . Diabetes Obes Metab. 1:1999;165-172.
32. Nakamura T., Funahashi T., Yamashita S., Nishida M., Nishida Y., Takahashi M., Hotta K., Kuriyama H., Kihara S., Ohuchi N., et al. Thiazolidinedione derivative improves fat distribution and multiple risk factors in subjects with visceral fat accumulation - double-blind placebo-controlled trial. Diabetes Res Clin Pract. 54:2001;181-190.
33. Antonucci T., Whitcomb R., McLain R., Lockwood D., Norris R.M. Impaired glucose tolerance is normalized by treatment with the thiazolidinedione troglitazone. Diabetes Care. 20:1997;188-193.
34. Tack C.J., Smits P., Demacker P.N., Stalenhoef A.F. Troglitazone decreases the proportion of small, dense LDL and increases the resistance of LDL to oxidation in obese subjects. Diabetes Care. 21:1998;796-799.
35. Pont F., Duvillard L., Florentin E., Gambert P., Verges B. High-density lipoprotein apolipoprotein A-I kinetics in obese insulin resistant patients an in vivo stable isotope study . Int J Obes Relat Metab Disord. 26:2002;1151-1158.
36. Barbier O., Torra I.P., Duguay Y., Blanquart C., Fruchart J.C., Glineur C., Staels B. Pleiotropic actions of peroxisome proliferator-activated receptors in lipid metabolism and atherosclerosis. Arterioscler Thromb Vasc Biol. 22:2002;717-726.
37. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial . JAMA. 273:1995;199-208.
38. Jones D.R., Schmidt R.J., Pickard R.T., Foxworthy P.S., Eacho P.I. Estrogen receptor-mediated repression of human hepatic lipase gene transcription. J Lipid Res. 43:2002;383-391.
39. Jin F.Y., Kamanna V.S., Kashyap M.L. Estradiol stimulates apolipoprotein A-I-but not A-II-containing particle synthesis and secretion by stimulating mRNA transcription rate in Hep G2 cells. Arterioscler Thromb Vasc Biol. 18:1998;999-1006.
40. Hulley S., Grady D., Bush T., Furberg C., Herrington D., Riggs B., Vittinghoff E. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women Heart and Estrogen/progestin Replacement Study (HERS) Research Group . JAMA. 280:1998;605-613.
41. Risks and benefits of estrogen plus progestin in healthy postmenopausal women principal results from the Women's Health Initiative randomized controlled trial . JAMA. 288:2002;321-333.
42. Harris W.S. n-3 fatty acids and lipoproteins comparison of results from human and animal studies . Lipids. 31:1996;243-252.